ATG dosing strategy for unrelated donor stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer in complete remission (CR1 or CR2) and need a stem cell transplant
- You have an available donor who is HLA-matched (genetically compatible)—sibling, unrelated, or half-matched
- You are between 14 and 65 years old
- Your liver and kidney function tests are near normal or better
- You do not have an active, uncontrolled infection or severe mental health condition
- You are able to care for yourself with minimal to moderate assistance (ECOG 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving anti-thymocyte globulin (ATG) based on a person's own body chemistry can reduce side effects and improve outcomes in stem cell transplants. It is for people with certain blood cancers who are in their first or second remission.
This trial is for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a half-matched donor. It compares two different doses of a medicine that helps prevent the donor cells from attacking the body (graft-versus-host disease).
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.